Pond, G. R., Armstrong, A. J., Wood, B. A., Brookes, M., Leopold, L. H., Berry, W. R., … Sonpavde, G. (2011). Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 29(15_suppl), 4582–4582. https://doi.org/10.1200/jco.2011.29.15_suppl.4582

Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and G. Sonpavde. “Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 4582–4582. https://doi.org/10.1200/jco.2011.29.15_suppl.4582.

Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Berry WR, et al. Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2011 May 20;29(15_suppl):4582–4582.

Pond, G. R., et al. “Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. 4582–4582. Crossref, doi:10.1200/jco.2011.29.15_suppl.4582.

Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Berry WR, De Wit R, Eisenberger MA, Tannock I, Sonpavde G. Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):4582–4582.